Zydus Healthcare launches generic anti-diabetic Dapagliflozi
Now open: Certificate Course in Management of Covid-19 by Govt. Of Gujarat and PlexusMDKnow more...Now open: Certificate Course in Management of Covid-19 by Govt. Of Gujarat and PlexusMDKnow more...
Drug firm Zydus Healthcare on 4th October said it has launched generic anti-diabetic Dapagliflozin tablets across the country under the brand name 'Dapaglyn' at highly affordable price to increase patient access.

Zydus Healthcare said in a statement:

• The company has launched its Dapagliflozin tablets in the strengths of 10 mg and 5 mg priced at Rs 17 and Rs 14, respectively, in India upon patent expiry of the product.

• A once-daily oral treatment indicated as an adjunct to diet and exercise, Dapaglyn aims to improve glycemic control in adults with Type 2 diabetes mellitus.

• Dapagliflozin is part of a newer class of medications called sodium-glucose co-transporter 2 (SGLT2) inhibitors. It lowers blood sugar by causing the kidneys to get rid of more glucose in the urine.

• Taking Dapagliflozin, along with lifestyle changes (e.g., diet, exercise, quitting smoking), and regularly checking one’s blood sugar may help patients manage their blood sugar levels and improve their health.

• With diabetes becoming a major health burden in India which has a patient population of almost 77 million diabetics, it is critical to have therapies which are affordable and accessible to patients from all sections of society.

Source: https://zyduscadila.com/public/pdf/pressrelease/PrReOct20Dapaglyn.pdf
Dr. D●●●a P●l and 5 others like this9 shares
Like
Comment
Share